94 related articles for article (PubMed ID: 12713834)
1. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase.
Biasotti B; Dallavalle S; Merlini L; Farina C; Gagliardi S; Parini C; Belfiore P
Bioorg Med Chem; 2003 May; 11(10):2247-54. PubMed ID: 12713834
[TBL] [Abstract][Full Text] [Related]
2. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.
Nadler G; Morvan M; Delimoge I; Belfiore P; Zocchetti A; James I; Zembryki D; Lee-Rycakzewski E; Parini C; Consolandi E; Gagliardi S; Farina C
Bioorg Med Chem Lett; 1998 Dec; 8(24):3621-6. PubMed ID: 9934482
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
4. New biophysical probes for structure-activity analyses of vacuolar-H+ -ATPase enzymes.
Dixon N; Pali T; Ball S; Harrison MA; Marsh D; Findlay JB; Kee TP
Org Biomol Chem; 2003 Dec; 1(24):4361-3. PubMed ID: 14685305
[TBL] [Abstract][Full Text] [Related]
5. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
[TBL] [Abstract][Full Text] [Related]
6. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
7. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
8. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.
Farina C; Gagliardi S; Nadler G; Morvan M; Parini C; Belfiore P; Visentin L; Gowen M
Farmaco; 2001; 56(1-2):113-6. PubMed ID: 11347950
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the indole class of vacuolar H(+)-ATPase inhibitors with lipid bilayers.
Fernandes F; Loura L; Koehorst RB; Dixon N; Kee TP; Hemminga MA; Prieto M
Biochemistry; 2006 Apr; 45(16):5271-9. PubMed ID: 16618115
[TBL] [Abstract][Full Text] [Related]
10. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
11. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
Visentin L; Dodds RA; Valente M; Misiano P; Bradbeer JN; Oneta S; Liang X; Gowen M; Farina C
J Clin Invest; 2000 Jul; 106(2):309-18. PubMed ID: 10903347
[TBL] [Abstract][Full Text] [Related]
12. Interaction of spin-labeled inhibitors of the vacuolar H+-ATPase with the transmembrane Vo-sector.
Dixon N; Páli T; Kee TP; Ball S; Harrison MA; Findlay JB; Nyman J; Väänänen K; Finbow ME; Marsh D
Biophys J; 2008 Jan; 94(2):506-14. PubMed ID: 17872954
[TBL] [Abstract][Full Text] [Related]
13. Solid phase synthesis of diamides as potential bone resorption inhibitors.
Edvinsson KM; Herslöf M; Holm P; Kann N; Keeling DJ; Mattsson JP; Nordén B; Shcherbukhin V
Bioorg Med Chem Lett; 2000 Mar; 10(5):503-7. PubMed ID: 10743958
[TBL] [Abstract][Full Text] [Related]
14. [3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase.
Mattsson JP; Keeling DJ
Biochim Biophys Acta; 1996 Apr; 1280(1):98-106. PubMed ID: 8634321
[TBL] [Abstract][Full Text] [Related]
15. Iejimalides show anti-osteoclast activity via V-ATPase inhibition.
Kazami S; Muroi M; Kawatani M; Kubota T; Usui T; Kobayashi J; Osada H
Biosci Biotechnol Biochem; 2006 Jun; 70(6):1364-70. PubMed ID: 16794315
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
17. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
18. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Niikura K; Nakajima S; Takano M; Yamazaki H
Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
[TBL] [Abstract][Full Text] [Related]
19. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity studies of the V-ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs.
Garcia-Rodriguez J; Mendiratta S; White MA; Xie XS; De Brabander JK
Bioorg Med Chem Lett; 2015 Oct; 25(20):4393-8. PubMed ID: 26372654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
